MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock.

(Nasdaq: MIRM) today announced that on March 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted ...

It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally.

We initiated the Phase 3 EXPAND study of LIVMARLI in broader settings of cholestatic pruritus, a significant growth opportunity for the brand. And beyond LIVMARLI, we achieved positive interim ...

LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions expected to complete enrollment in 2026. Expect to initiate Phase 2 study for MRM-3379 in Fragile X Syndrome (FXS) in 2025.

AlphaQuest LLC increased its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 969.6% in the 4th quarter ...

inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. Receive News & Ratings for Mirum Pharmaceuticals ...